Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 255.29
(-2.5%)
USD 255.29
(-2.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.05 Billion USD | 9.34% |
| 2022 | 3.7 Billion USD | 21.26% |
| 2021 | 3.05 Billion USD | 27.78% |
| 2020 | 2.39 Billion USD | 149.97% |
| 2019 | 956.44 Million USD | 250.55% |
| 2018 | 272.83 Million USD | 19.51% |
| 2017 | 228.29 Million USD | -33.36% |
| 2016 | 342.58 Million USD | 181.28% |
| 2015 | 121.79 Million USD | 27.76% |
| 2014 | 95.33 Million USD | 76.99% |
| 2013 | 53.86 Million USD | 11.42% |
| 2012 | 48.34 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.04 Billion USD | -0.17% |
| 2024 Q3 | 4.17 Billion USD | 3.99% |
| 2024 Q2 | 4.01 Billion USD | -0.77% |
| 2023 Q4 | 4.05 Billion USD | 1.14% |
| 2023 Q3 | 4 Billion USD | 5.1% |
| 2023 Q2 | 3.81 Billion USD | 4.36% |
| 2023 Q1 | 3.65 Billion USD | -1.44% |
| 2023 FY | 4.05 Billion USD | 9.34% |
| 2022 Q3 | 3.6 Billion USD | 14.22% |
| 2022 Q2 | 3.15 Billion USD | 4.02% |
| 2022 Q1 | 3.03 Billion USD | -0.74% |
| 2022 FY | 3.7 Billion USD | 21.26% |
| 2022 Q4 | 3.7 Billion USD | 2.82% |
| 2021 Q3 | 2.71 Billion USD | 2.27% |
| 2021 FY | 3.05 Billion USD | 27.78% |
| 2021 Q4 | 3.05 Billion USD | 12.47% |
| 2021 Q2 | 2.65 Billion USD | 14.04% |
| 2021 Q1 | 2.32 Billion USD | -2.58% |
| 2020 Q2 | 1.97 Billion USD | 112.35% |
| 2020 Q4 | 2.39 Billion USD | 14.27% |
| 2020 FY | 2.39 Billion USD | 149.97% |
| 2020 Q1 | 929.89 Million USD | -2.78% |
| 2020 Q3 | 2.09 Billion USD | 5.96% |
| 2019 Q3 | 934.53 Million USD | -2.57% |
| 2019 Q1 | 467.01 Million USD | 71.17% |
| 2019 FY | 956.44 Million USD | 250.55% |
| 2019 Q4 | 956.44 Million USD | 2.34% |
| 2019 Q2 | 959.21 Million USD | 105.39% |
| 2018 Q2 | 168.58 Million USD | 0.15% |
| 2018 Q1 | 168.33 Million USD | -26.27% |
| 2018 FY | 272.83 Million USD | 19.51% |
| 2018 Q4 | 272.83 Million USD | 38.12% |
| 2018 Q3 | 197.53 Million USD | 17.17% |
| 2017 FY | 228.29 Million USD | -33.36% |
| 2017 Q4 | 228.29 Million USD | -23.76% |
| 2017 Q3 | 299.44 Million USD | -3.81% |
| 2017 Q2 | 311.31 Million USD | 2.74% |
| 2017 Q1 | 303.02 Million USD | -11.55% |
| 2016 Q4 | 342.58 Million USD | 14.99% |
| 2016 FY | 342.58 Million USD | 181.28% |
| 2016 Q1 | 66.36 Million USD | 6.88% |
| 2016 Q2 | 283.68 Million USD | 327.43% |
| 2016 Q3 | 297.94 Million USD | 5.03% |
| 2015 Q4 | 62.09 Million USD | 8.73% |
| 2015 Q3 | 57.11 Million USD | -14.24% |
| 2015 Q2 | 66.59 Million USD | -17.47% |
| 2015 Q1 | 80.69 Million USD | -15.36% |
| 2015 FY | 121.79 Million USD | 27.76% |
| 2014 Q2 | 53.74 Million USD | -35.89% |
| 2014 Q3 | 56.84 Million USD | 5.78% |
| 2014 Q4 | 95.33 Million USD | 67.7% |
| 2014 Q1 | 83.83 Million USD | 55.63% |
| 2014 FY | 95.33 Million USD | 76.99% |
| 2013 FY | 53.86 Million USD | 11.42% |
| 2013 Q2 | 53.06 Million USD | 6.67% |
| 2013 Q3 | 54.89 Million USD | 3.45% |
| 2013 Q4 | 53.86 Million USD | -1.88% |
| 2013 Q1 | 49.75 Million USD | 2.91% |
| 2012 Q4 | 48.34 Million USD | 0.0% |
| 2012 FY | 48.34 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -549.103% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -3112.178% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -555.737% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -1430.03% |
| bluebird bio, Inc. | 424.62 Million USD | -853.908% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -5790.9% |
| Imunon, Inc. | 8.53 Million USD | -47383.25% |
| Editas Medicine, Inc. | 150.05 Million USD | -2599.342% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 80.308% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -15.548% |
| Myriad Genetics, Inc. | 312.9 Million USD | -1194.511% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -297.344% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -730.943% |
| Verastem, Inc. | 71.18 Million USD | -5590.137% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 94.117% |
| Waters Corporation | 3.47 Billion USD | -16.511% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 92.193% |
| Biogen Inc. | 12.04 Billion USD | 66.373% |
| Nektar Therapeutics | 267.04 Million USD | -1416.789% |
| Perrigo Company plc | 6.04 Billion USD | 32.952% |
| Dynavax Technologies Corporation | 375.02 Million USD | -980.071% |
| Illumina, Inc. | 4.36 Billion USD | 7.226% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -11414.657% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -1969.36% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -1479.281% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -10761.643% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -114.307% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -4813.717% |
| Evolus, Inc. | 209.68 Million USD | -1831.7% |
| Adicet Bio, Inc. | 37.12 Million USD | -10811.972% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -9969.418% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 43.007% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -512.982% |
| FibroGen, Inc. | 585.72 Million USD | -591.537% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 17.639% |
| OPKO Health, Inc. | 622.47 Million USD | -550.709% |
| Homology Medicines, Inc. | 118.53 Million USD | -3317.212% |
| Geron Corporation | 146.12 Million USD | -2671.92% |
| Exelixis, Inc. | 678.44 Million USD | -497.031% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -20080.978% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -32216.292% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -1514.99% |
| Zoetis Inc. | 9.29 Billion USD | 56.423% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -919.618% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -8136.79% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 21.346% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -8261.078% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -55.587% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -68.404% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -3427.962% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -145.566% |
| Blueprint Medicines Corporation | 918.64 Million USD | -340.926% |
| Insmed Incorporated | 1.66 Billion USD | -143.749% |
| TG Therapeutics, Inc. | 169.08 Million USD | -2295.555% |
| Incyte Corporation | 1.59 Billion USD | -154.387% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -241.643% |